A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Adhikari, Suman; Nath, Priyatosh; Das, Alakesh; Datta, Abhijit; Baildya, Nabajyoti; Duttaroy, Asim K.; Pathak, Surajit

doi:10.1016/j.biopha.2024.116211

Cited by 43 publications

(5 citation statements)

References 263 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous research studies demonstrate that cobalt, nickel, and copper compounds have a better biological profile as anticonvulsive, anti-inflammatory, antibacterial, and antifungal agents 5 . Numerous clinical studies have emphasized that complexes play a fascinating role in the creation of a range of anti-tumor medicines, and the variety of them additionally relies on the ligand coupled to the metal 6 . An important characteristic of copper derivatives is their usage in producing anticancer medications, which could be an option in addition to platinum-based therapeutics since copper compounds aren't as toxic and their mode of action is relatively simpler than other therapies for cancer 7 .…”

Section: Introductionmentioning

confidence: 99%

Synthesis, characterization, biological potency, and molecular docking of Co2+, Ni2+ and Cu2+ complexes of a benzoyl isothiocyanate based ligand

Al-Farraj,

Younis,

El-Reash

2024

Sci Rep

View full text Add to dashboard Cite

The primary objective of the present study was to produce metal complexes of H4DAP ligand (N,N'-((pyridine-2,6-diylbis(azanediyl))bis(carbonothioyl))dibenzamide) derived from 2,6-diaminopyridine and benzoyl isothiocyanate with either ML or M2L stoichiometry. There are three distinct coordination complexes obtained with the formulas [Co(H2DAP)]·H2O, [Ni2(H2DAP)Cl2(H2O)2]·H2O, and [Cu(H4DAP)Cl2]·3H2O. The confirmation of the structures of all derivatives was achieved through the utilization of several analytical techniques, including FT-IR, UV–Vis, NMR, GC–MS, PXRD, SEM, TEM analysis, and QM calculations. Aiming to analyze various noncovalent interactions, topological methods such as QTAIM, NCI, ELF, and LOL were performed. Furthermore, the capacity of metal–ligand binding was examined by fluorescence emission spectroscopy. An in vitro investigation showed that the viability of MDA-MB-231 and HepG-2 cells was lower when exposed to the manufactured Cu2+ complex, in comparison to the normal cis-platin medication. The compounds were further evaluated for their in vitro antibacterial activity. The Ni2+ complex has shown promising activity against all tested pathogens, comparable to the reference drugs Gentamycin and Ketoconazole. Furthermore, a computational docking investigation was conducted to further examine the orientation, interaction, and conformation of the recently created compounds on the active site of the Bcl-2 protein.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis, characterization, biological potency, and molecular docking of Co2+, Ni2+ and Cu2+ complexes of a benzoyl isothiocyanate based ligand

Al-Farraj,

Younis,

El-Reash

2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Based on the most recent data, cancer accounts for one out of every six disease-related deaths; more specifically, one-fifth of men, as well as one-sixth of women, is detected with malignancy during their lifespan; one in eight males and eleven women pass away from it. Australia and New Zealand dominate the world in terms of cancer incidence and death rates, followed by North America and Europe (Siegel et al, 2023;Adhikari et al, 2024). Over the years, this complex disease has grown exponentially, leading to remarkable advances in cancer diagnosis and treatment (Bhattacharjee and Mukherjee, 2016;Das et al, 2021;Boga and Bisgin, 2022;Sen et al, 2022;Kesavan et al, 2023;.…”

Section: Introductionmentioning

confidence: 99%

Metal-Based Drugs in Cancer Therapy

Nath,

Datta,

Das

et al. 2024

IJERR

View full text Add to dashboard Cite

Metal-based drugs have emerged as pivotal therapeutics in cancer therapy, enlightening a path toward innovative and effective treatment strategies. Platinum-based therapeutics, notably cisplatin, carboplatin, and oxaliplatin, have transformed the landscape of cancer treatment, setting the stage for the development of next-generation metal-based compounds. Delving into the principles governing the design of metal-based drugs, this article navigates through their intricate coordination chemistry, targeted delivery approaches, and mechanisms of action. Notably, metal-based compounds form covalent bonds with DNA, disrupting vital cellular processes and inducing apoptosis in cancerous tissues. Even though contemporary chemotherapy as well as radiotherapeutic methods have greatly increased patient survival rates, disease recurrence still represents a fatal danger. The probability of metastasis and the drug resistance are increased by the incomplete clearance of neoplastic tissues from the body. This review explores the compelling journey of metal-based compounds, from their historical significance in ancient remedies to their pivotal role in modern oncology, and also discusses the recent advancements and emerging trends that promise to shape the future of metallodrugs. The shining promise of metal-based drugs in cancer remedies holds the potential to revolutionize treatment paradigms, offering hope and resilience in the ongoing battle against one of humanity's most relentless adversaries.

show abstract

“…Since the discovery of cisplatin in the 1960s and the success of its use to treat cancers [1], researchers in bioinorganic chemistry have first focused on platinum derivatives, which are of current use to treat testicular, ovarian, and lung cancers [2]. The search for metallo-drugs more efficient than platinum complexes, while having negligible side effects, has attracted much interest, as recently emphasized in a review of in vivo studies of the anticancer activities of metal complexes [3]. Among the metals that have been thoroughly examined for potential applications as anticancer agents are mainly ruthenium, titanium, gold, and copper.…”

Section: Introductionmentioning

confidence: 99%

Dendritic Pyridine–Imine Copper Complexes as Metallo-Drugs

Laurent,

Maraval,

Bernardes-Génisson

et al. 2024

Molecules

View full text Add to dashboard Cite

Since the discovery of cisplatin in the 1960s, the search for metallo-drugs that are more efficient than platinum complexes with negligible side effects has attracted much interest. Among the other metals that have been examined for potential applications as anticancer agents is copper. The interest in copper was recently boosted by the discovery of cuproptosis, a recently evidenced form of cell death mediated by copper. However, copper is also known to induce the proliferation of cancer cells. In view of these contradictory results, there is a need to find the most suitable copper chelators, among which Schiff-based derivatives offer a wide range of possibilities. Gathering several metal complexes in a single, larger entity may provide enhanced properties. Among the nanometric objects suitable for such purpose are dendrimers, precisely engineered hyperbranched macromolecules, which are outstanding candidates for improving therapy and diagnosis. In this review article, we present an overview of the use of a particular Schiff base, namely pyridine–imine, linked to the surface of dendrimers, suitable for complexing copper, and the use of such dendrimer complexes in biology, in particular against cancers.

show abstract

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Cited by 43 publications

References 263 publications

Synthesis, characterization, biological potency, and molecular docking of Co2+, Ni2+ and Cu2+ complexes of a benzoyl isothiocyanate based ligand

Synthesis, characterization, biological potency, and molecular docking of Co2+, Ni2+ and Cu2+ complexes of a benzoyl isothiocyanate based ligand

Metal-Based Drugs in Cancer Therapy

Dendritic Pyridine–Imine Copper Complexes as Metallo-Drugs

Contact Info

Product

Resources

About